Management of metastatic colorectal cancer (mCRC) of the liver presents a complex challenge to oncologists and multidisciplinary treatment teams. Selective internal radiation therapy (SIRT) with SIR-Spheres^® Y-90 resin microspheres , administered by an interventional radiologist, is an FDA approved and National Comprehensive Cancer Network (NCCN) category 2A recommended local therapy for the treatment of mCRC liver tumors. Approximately 73,000 treatment doses have been administered in more than 1000 medical centers worldwide.

In addition, new data from an array of large, multi-center, international studies may support expanded options for SIR-Spheres Y-90 resin microspheres throughout a mCRC patient’s treatment paradigm. Results of the SIRFLOX study published in 2016 in the Journal of Clinical Oncology revealed stabilization of cancer in the liver for 7.9 months when SIR-Spheres Y-90 resin microspheres was combined with 1st line chemotherapy vs 1st line chemotherapy alone. New first-line mCRC data from the 1100-patient combined SIRFLOX, FOXFIRE and FOXFIRE Global studies will be presented in the first half of 2017.